Welcome to our dedicated page for Affimed news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed stock.
Affimed N.V. reports developments as a clinical-stage immuno-oncology company focused on innate cell engager, or ICE, molecules generated from its proprietary ROCK platform. Company news centers on AFM24 in non-small cell lung cancer, including monotherapy and combinations with atezolizumab, and acimtamig in combination with AlloNK, as well as scientific meeting presentations and clinical data updates.
Affimed’s recent corporate updates also cover its filing for the opening of insolvency proceedings in Germany and Nasdaq listing matters, including deficiency notices, trading suspension, and delisting of its common shares.
Affimed has announced the successful completion of the first dose cohort in a Phase 1/2a clinical trial for AFM24, a novel bispecific innate cell engager targeting EGFR-expressing malignancies. No dose-limiting toxicities were observed, allowing progression to the second dose cohort. While efficacy was not expected at this stage, the trial aims to gather data on the safety and potential effectiveness of AFM24 as a treatment option. The company emphasizes that AFM24 could provide a new mechanism of action that utilizes innate immunity to combat cancer.
Heidelberg, Germany, June 16, 2020 – Affimed N.V. (Nasdaq: AFMD) will release its first quarter 2020 financial results on June 23, 2020, at 8:30 a.m. EDT, followed by a conference call. Investors can join via phone or webcast, with details provided in the PR. Additionally, CEO Dr. Adi Hoess will participate in a fireside chat at the BMO Healthcare Conference on the same day at 1:30 p.m. EDT. Affimed focuses on immuno-oncology, developing therapies for various cancers, including studies for AFM13 and AFM24.
Affimed N.V. (Nasdaq: AFMD) announced the appointment of Angus Smith as the new Chief Financial Officer, effective July 13, 2020. This appointment completes the company's leadership team. Smith brings extensive biopharmaceutical experience, having previously served as CFO at Rockwell Medical. His expertise in financial management and US capital markets is expected to enhance Affimed's strategic position during its upcoming growth phase. The company develops innovative cancer treatments using its ROCK® platform and is advancing clinical studies for therapies targeting hematologic and solid tumors.
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, will have its CEO, Dr. Adi Hoess, present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 8:00 a.m. Eastern Time. The presentation will be available via a live webcast on Affimed’s website and accessible for 30 days post-event. Affimed focuses on innovative therapies to empower patients against cancer, currently developing AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma, and AFM24 for advanced EGFR-expressing solid tumors. For further details, visit www.affimed.com.
Affimed N.V. (Nasdaq: AFMD) announced participation in the AACR Virtual Annual Meeting II on June 22-24, 2020, with two studies on innate cell engagers from its ROCK® platform. Researchers from Affimed will present data on AFM24, a bispecific EGFR/CD16A Innate Cell Engager, and RO7297089, an anti-BCMA/CD16a antibody for multiple myeloma. A live teleconference will be held on May 15, 2020, at 8 am Eastern to discuss the abstracts and updates. Affimed continues to advance its clinical programs targeting cancer treatment.
Summary not available.